Advances in Lafora Disease and Related Polyglucosan Disorders Therapy: From Drug Repurposing to Gene-Based Approaches

Lafora disease (LD) is a fatal progressive myoclonus epilepsy caused by biallelic pathogenic variants in EPM2A or NHLRC1, resulting in the accumulation of poorly branched, insoluble glycogen aggregates known as Lafora bodies (LBs). Over the past decade, advances in understanding LD pathogenesis have progressively redefined the role of abnormal glycogen metabolism and highlighted the central contribution of polyglucosan accumulation to disease pathogenesis. These mechanistic insights have substantially changed the therapeutic perspective, shifting the focus from symptomatic management toward interventions aimed at modifying the underlying disease processes. This review provides an updated overview of therapeutic advances reported between 2022 and 2026, with a primary focus on LD while highlighting selected developments in the related polyglucosan disorders Adult Polyglucosan Body Disease and Glycogen Storage Disease type IV. Despite major challenges remaining, recent progress provides a rapidly evolving framework for the development of disease-modifying treatments for LD and offers relevant insights into the broader therapeutic potential and limitations of targeting pathological glycogen in polyglucosan disorders.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical and BioTech Industry
Published
2026-11-13
DOI
https://doi.org/10.3390/jpbi3040029
Primary Topic
Glycogen Storage Diseases and Myoclonus
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Advances in Lafora Disease and Related Polyglucosan Disorders Therapy: From Drug Repurposing to Gene-Based Approaches

Marco Salvatore, Paola Torreri, Giorgia Buoncuore, Benedetta Salvucci
1 links
Journal of Pharmaceutical and BioTech Industry
Glycogen Storage Diseases and Myoclonus
article

Advances in Lafora Disease and Related Polyglucosan Disorders Therapy: From Drug Repurposing to Gene-Based Approaches

Marco Salvatore, Paola Torreri, Giorgia Buoncuore, Benedetta Salvucci
article en

Abstract

Lafora disease (LD) is a fatal progressive myoclonus epilepsy caused by biallelic pathogenic variants in EPM2A or NHLRC1, resulting in the accumulation of poorly branched, insoluble glycogen aggregates known as Lafora bodies (LBs). Over the past decade, advances in understanding LD pathogenesis have progressively redefined the role of abnormal glycogen metabolism and highlighted the central contribution of polyglucosan accumulation to disease pathogenesis. These mechanistic insights have substantially changed the therapeutic perspective, shifting the focus from symptomatic management toward interventions aimed at modifying the underlying disease processes. This review provides an updated overview of therapeutic advances reported between 2022 and 2026, with a primary focus on LD while highlighting selected developments in the related polyglucosan disorders Adult Polyglucosan Body Disease and Glycogen Storage Disease type IV. Despite major challenges remaining, recent progress provides a rapidly evolving framework for the development of disease-modifying treatments for LD and offers relevant insights into the broader therapeutic potential and limitations of targeting pathological glycogen in polyglucosan disorders.

Journal of Pharmaceutical and BioTech IndustryVol. 3(4)
Istituto Superiore di Sanità (IT)
Good health and well-being
Glycogen Storage Diseases and Myoclonus
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon